News

Managed Healthcare Executive2d
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
PharmExec13d
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Applied Clinical Trials Online13d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Fierce Pharma13d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.